These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1091 related items for PubMed ID: 28233086

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resin Versus Glass Microspheres for 90Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry.
    Van Der Gucht A, Jreige M, Denys A, Blanc-Durand P, Boubaker A, Pomoni A, Mitsakis P, Silva-Monteiro M, Gnesin S, Lalonde MN, Duran R, Prior JO, Schaefer N.
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G.
    World J Gastroenterol; 2016 Dec 21; 22(47):10406-10414. PubMed ID: 28058021
    [Abstract] [Full Text] [Related]

  • 4. Metabolic activity assessment by 18 F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization.
    Kim DY, Lee HW, Kang W, Kim GM, Won JY, Yun M.
    J Gastroenterol Hepatol; 2021 Jun 21; 36(6):1679-1684. PubMed ID: 33226706
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization.
    Puranik AD, Rangarajan V, Gosavi A, Shetty N, Gala K, Kulkarni S, Mohite A, Patkar S, Goel M, Shrikhande SV, Ramaswamy A, Ostwal V, Purandare NC, Agrawal A, Shah S.
    Nucl Med Commun; 2021 Mar 01; 42(3):337-344. PubMed ID: 33306631
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.
    Hyun SH, Eo JS, Lee JW, Choi JY, Lee KH, Na SJ, Hong IK, Oh JK, Chung YA, Song BI, Kim TS, Kim KS, Moon DH, Yun M.
    Eur J Nucl Med Mol Imaging; 2016 Aug 01; 43(9):1638-45. PubMed ID: 26936852
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
    Hwang SH, Hong HS, Kim D, Kim GM, Lee HW, Lee M, Kim DY, Park MA, Yun M.
    Clin Nucl Med; 2022 Jun 01; 47(6):e437-e443. PubMed ID: 35384891
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription.
    Ho CL, Chen S, Cheung SK, Leung YL, Cheng KC, Wong KN, Wong YH, Leung TWT.
    Eur J Nucl Med Mol Imaging; 2018 Nov 01; 45(12):2110-2121. PubMed ID: 29948107
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim MJ, Kim YS, Cho YH, Jang HY, Song JY, Lee SH, Jeong SW, Kim SG, Jang JY, Kim HS, Kim BS, Lee WH, Park JM, Lee JM, Lee MH, Choi DL.
    Korean J Intern Med; 2015 May 01; 30(3):308-15. PubMed ID: 25995661
    [Abstract] [Full Text] [Related]

  • 16. Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma.
    Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, Denys A, Depeursinge A, Schaefer N.
    Oncotarget; 2018 Jan 12; 9(4):4549-4558. PubMed ID: 29435123
    [Abstract] [Full Text] [Related]

  • 17. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis.
    Filippi L, Di Costanzo GG, D'Agostini A, Tortora R, Pelle G, Cianni R, Schillaci O, Bagni O.
    Nucl Med Commun; 2018 Sep 12; 39(9):845-852. PubMed ID: 29901488
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Significance of ¹⁸F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study.
    Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim DY, Kim SU, Moon DH, Lee JD, Yun M.
    J Nucl Med; 2016 Apr 12; 57(4):509-16. PubMed ID: 26742711
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.